Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and raises the price target from $43 to $45.
September 11, 2023 | 2:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst maintains an Outperform rating on Crinetics Pharmaceuticals and raises the price target from $43 to $45.
The news of Baird maintaining an Outperform rating and raising the price target for Crinetics Pharmaceuticals is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100